logo
logo

Sofinnova Partners Announces Three New Investments From Its Fund Dedicated To Italian Scientific Research

Sofinnova Partners Announces Three New Investments From Its Fund Dedicated To Italian Scientific Research

06/30/21, 8:07 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/FR.svgparis
Industry
medical device
medical
biotechnology
health care
Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today three new investments from the Sofinnova Telethon Fund, its early-stage fund dedicated to investments in rare, genetic diseases. The startups, AAVantgarde Bio, Alia Therapeutics, and Borea Therapeutics, are developing promising new therapies for rare, genetic diseases.

Company Info

Company
Julier Medical
Location
paris, ile de france, france
Additional Info
Julier is developing a next generation mechanical thrombectomy solution for the removal of thrombus and revascularization of patients experiencing Acute Ischemic Strokes. The core technology is derived from the work of two serial medtech entrepreneurs, Laurent Grandidier and Niall Behan.

Related People